Cosmos Health Inc. (COSM) Stock Price & How to Invest

Cosmos Health Inc. is a small, vertically integrated global healthcare group headquartered in Greece and listed on Nasdaq under COSM. Its business has two broad parts. The larger, established part distributes pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter medicines, to retail pharmacies and wholesalers through subsidiaries in Greece and the UK. The second, higher-margin part is a portfolio of proprietary brands, most importantly the Sky Premium Life nutraceutical and supplement line, plus names like Mediterranation, bio-bebe, NOOR Collagen, and the C-Sept and C-Scrub lines. The strategy is to grow the branded, owned-product side, which carries better margins than pure distribution, while expanding into new markets and categories such as skincare and prescription medicines.

In 2026 the story is revenue growth against persistent losses and a fragile share price. Full-year 2025 revenue was about $65 million, up roughly 20% year over year, but the company still lost money, and 2026 quarterly revenue has continued to grow at around 30%. Management has issued multi-year guidance targeting roughly $200 million in revenue and positive adjusted EBITDA by 2029, an ambitious jump from today. Recent moves include taking Sky Premium Life to all 27 EU member states through the Skroutz e-commerce platform, entering the US skincare market, launching a subscription model for NOOR Collagen, and a Greek distribution partnership for a prescription diabetes medicine. At the same time, the stock trades well below $1 and Cosmos received a Nasdaq extension, into late 2026, to regain the $1.00 minimum bid price, with a reverse stock split described as a last resort. The company has also authorized a share buyback, an unusual step for a micro-cap in bid-price trouble.

The overriding risks are financial and structural rather than operational. Cosmos is lossmaking despite growing revenue, so it depends on continued execution and, potentially, more capital to fund expansion. Its history of reverse stock splits, including a 1-for-25 split in 2022, and past share issuance means dilution has repeatedly hurt long-term holders, and further dilution or another reverse split is a live possibility. The stock trades well below $1 and faces a Nasdaq minimum-bid-price deadline in late 2026; failure to regain compliance could lead to delisting, which would sharply reduce liquidity and visibility. As a micro-cap, the shares are thinly traded and highly volatile, and press-release-driven news flow can move the price far more than fundamentals justify. Multi-year guidance toward roughly $200 million in revenue is aspirational and far above current results, so there is meaningful risk it is not met.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cosmos Health Inc.'s investor relations page or your broker.

• Revenue (2025 full year): ~$65 million, up roughly 20% year over year
• Revenue (2026 quarterly): Q1 2026 ~$17.9 million, up ~31%; Q2 2026 guided to roughly $19 million
• Profitability: Still net lossmaking; full-year 2025 net loss on the order of $19 million
• Long-term guidance: Management targets ~$200 million revenue and positive adjusted EBITDA by 2029 (aspirational, far above current results)
• Market cap: Micro-cap, roughly in the low tens of millions of dollars; stock trades well under $1
• Listing status: Nasdaq extension into late 2026 to regain the $1.00 minimum bid price; reverse split described as a last resort

Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Cosmos is lossmaking, price-to-earnings multiples do not apply, and the market values it mainly on revenue growth and the credibility of its 2029 targets rather than current profit. Share counts have shifted with past issuance and a prior reverse split, so market cap and per-share figures should be checked live. For a sub-$1 micro-cap facing a listing deadline, capital-structure and delisting risk matter more to the stock than any single quarter's sales.

There are three common ways to get COSM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so COSM sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where COSM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Cosmos Health is a lossmaking micro-cap growing revenue via pharma distribution and its Sky Premium Life supplement brand, but it trades under $1 with a Nasdaq compliance deadline and a history of reverse splits and dilution. It is a high-risk speculation on a turnaround, not a stable healthcare holding.